ABOUT BIOMOBIE
——
Biomobie is a regenerative medicine company with multiple patents for the treatment and prevention of cardiovascular diseases (China Patent No.: ZL 201110083275.2, US Patent No.: US 8,968,172 B2). Headquartered in Shanghai, China. We conducts medical clinical trials at various institutions, including Brigham and Women's Hospital affiliated with Harvard Medical School, Mayo Clinic in the United States, and Fuwai Hospital Chinese Academy of Medical Sciences. The research center, product design center, and product manufacturing base are located in Silicon Valley, USA, and Shanghai.
Collaborating with several medical institutions, Biomobie has broken through the limitations of traditional drugs. Taking vascular microcirculation disorders, a major cause of chronic diseases, as the target for treatment, we have non-invasive Bioboosti® bioelectric technology to repair damaged vascular microcirculation. This approach aims to improve conditions related to cardiovascular and other microcirculation-related diseases. Bioboosti® by BIomobie has obtained market access approval for Class II medical devices for hypertension from China's NMPA and is registered as a Class I medical device with the U.S. FDA.
PRODUCT CENTER
——